title: Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer.
abstract: BACKGROUND
  The type 2 cytokine interleukin (IL)-10 has been reported to inhibit the antitumour activity of the regional immunity against various neoplasms. Certain lung cancers produce IL-10, but the clinical significance of IL-10 expression is not well understood.
  
  
  METHODS
  We examined IL-10 and IL-10 receptor (IL-10R) mRNA expression in 82 non-small-cell lung cancers (NSCLC) by reverse transcription-polymerase chain reaction (RT-PCR) assay. Immunohistochemistry (IHC) and enzyme immunoassay (EIA) were applied to evaluate the cellular localisation and the serum levels of IL-10.
  
  
  RESULTS
  RT-PCR assay revealed IL-10 mRNA expression in 68 (83%) of 82 NSCLC surgical specimens (40 of 50 adenocarcinomas, 22 of 26 squamous cell carcinomas, 5 of 5 large-cell carcinomas, 1 of 1 adenosquamous-cell carcinoma). RT-PCR assay also revealed IL-10R mRNA expression in 79 cases of NSCLC (96.1%). IL-10 expression was confirmed within tumour cells by IHC. EIA showed no significant serum IL-10 elevation in the 12 NSCLC positive for IL-10 mRNA expression (0-2.99 pg/ml). The NSCLC patients with IL-10 production showed significantly poorer prognosis than those without IL-10 production (P < 0.05, Kaplan Meier, log-rank test).
  
  
  CONCLUSIONS
  These results suggested that the cytoplasmic IL-10 correlated to clinical prognosis, and that IL-10 expression is a prognostic factor for NSCLC.
authors.affiliation: Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Hatanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Abe
authors.forename: T
authors.initials: T
authors.lastname: Kamiya
authors.forename: F
authors.initials: F
authors.lastname: Morino
authors.forename: J
authors.initials: J
authors.lastname: Nagata
authors.forename: T
authors.initials: T
authors.lastname: Tokunaga
authors.forename: Y
authors.initials: Y
authors.lastname: Oshika
authors.forename: H
authors.initials: H
authors.lastname: Suemizu
authors.forename: H
authors.initials: H
authors.lastname: Kijima
authors.forename: T
authors.initials: T
authors.lastname: Tsuchida
authors.forename: H
authors.initials: H
authors.lastname: Yamazaki
authors.forename: H
authors.initials: H
authors.lastname: Inoue
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
authors.forename: Y
authors.initials: Y
authors.lastname: Ueyama
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000276:immunology* / Q000503:physiopathology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016753:Interleukin-10 / Q000494:pharmacology*; D008175:Lung Neoplasms; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D018123:Receptors, Interleukin / Q000187:drug effects / Q000502:physiology*; D053701:Receptors, Interleukin-10; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D012333:RNA, Messenger; D018123:Receptors, Interleukin; D053701:Receptors, Interleukin-10; D016753:Interleukin-10